Hunan Er-Kang Pharmaceutical Co., Ltd

SZSE:300267 Stock Report

Market Cap: CN¥5.9b

Hunan Er-Kang Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Qingrong Sun

Chief executive officer

CN¥335.7k

Total compensation

CEO salary percentagen/a
CEO tenure5.1yrs
CEO ownershipn/a
Management average tenure5.1yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%

Sep 30
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%

Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?

Sep 26
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?

What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You

Aug 08
What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You

Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?

Jun 03
Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?

Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now

Mar 27
Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now

CEO

Qingrong Sun (38 yo)

5.1yrs

Tenure

CN¥335,700

Compensation

Mr. Qingrong Sun is General Manager of Hunan Er-Kang Pharmaceutical Co., Ltd from November 14, 2019 and serves as Director from November 14, 2022. He joined Hunan Er-Kang Pharmaceutical Co., Ltd. in July 2...


Leadership Team

NamePositionTenureCompensationOwnership
Qingrong Sun
GM & Non-Independent Director5.1yrsCN¥335.70kno data
Zhao Xun
CFO & Non Independent Directorno dataCN¥389.10kno data
Xiangyang Shi
Deputy GM & Non Independent Directorno dataCN¥535.10kno data
Jishun Gu
Deputy GM & Board Secretary4.8yrsCN¥514.20k0.0017%
CN¥ 102.6k
Licheng Zhang
Deputy General Managerno dataCN¥422.70kno data
Wang Hui
Deputy General Manager5.1yrsCN¥365.30kno data

5.1yrs

Average Tenure

42.5yo

Average Age

Experienced Management: 300267's management team is seasoned and experienced (5.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Qingrong Sun
GM & Non-Independent Director2.1yrsCN¥335.70kno data
Zhao Xun
CFO & Non Independent Director5.1yrsCN¥389.10kno data
Xiangyang Shi
Deputy GM & Non Independent Director6.3yrsCN¥535.10kno data
Fangwen Shuai
Chairman of the Boardno dataCN¥512.60k41.38%
CN¥ 2.4b
Junwen Wang
Independent Director5.1yrsCN¥150.00kno data
Wuzhen Jiang
Independent Director5.1yrsCN¥150.00kno data
Qing Peng
Chairman of Supervisory Board3.6yrsno datano data
Xue Tan
Independent Director2.1yrsCN¥150.00kno data
Haiyi Li
Non-Employee Supervisor2.1yrsno datano data
Hong Wang
Supervisor2.1yrsno datano data

3.6yrs

Average Tenure

50yo

Average Age

Experienced Board: 300267's board of directors are considered experienced (3.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 06:57
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hunan Er-Kang Pharmaceutical Co., Ltd is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Shuchang LiuChangjiang Securities Co. LTD.
Jing QiangChina International Capital Corporation Limited